alexa Engineering PEGylated Gold Nanoparticles For Tumor Target Drug Delivery
ISSN: 2157-7439

Journal of Nanomedicine & Nanotechnology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

3rd International Conference on Nanotek & Expo
December 02-04, 2013 Hampton Inn Tropicana, Las Vegas, NV, USA

Giulio F. Paciotti
Accepted Abstracts: J Nanomed Nanotechnol
DOI: 10.4172/2157-7439.S1.015
Abstract
One of the most effective treatments for solid organ malignancies is a surgical procedure known as isolated limb and organ perfusion (ILP) in which a vascular disrupting agent, such as Tumor Necrosis Factor Alpha (TNF) and chemotherapy are perfused through a tumor-bearing limb. A single treatment with this combination, albeit delivered through heroic surgical perfusion, results in 60-85% response rates in cancer patients that are refractory to conventional therapies. Key to the success of ILP is not only the semi-targeted delivery of TNF and chemotherapy, achieved by the surgical perfusion, but the temporal sequence in which these active pharmaceutical ingredients (APIs) are administered. Briefly, the preclinical data reveal that the delivery of TNF must precede that of the chemotherapy, as its initial delivery induces near instantaneous vascular leak within the tumor vasculature and a concomitant reduction in the interstitial fluid pressure (IFP) within the tumor. The elimination of the IFP gradient enhances uptake and efficacy of the follow-on chemotherapy. Nevertheless, as promising as ILP appears it only represents a regional solution for treating solid tumors without broad application to disseminated disease. In an effort to achieve results similar to ILP CytImmune Sciences has, over the past decade, engineered 27 nm particles of PEGylated colloidal gold, into a family of tumor targeting nanomedicines. Each nanomedicine is designed to address specific barriers of drug delivery in the treatment of solid tumors. The first of these nanodrugs is termed CYT-6091 targets the delivery of TNF as a single agent to solid tumors. To date the sum of our preclinical data show that CYT-6091, by targeting the TNF to the site of disease, induces progressive disruption of the tumor neovasculature resulting in potent anti-tumor responses. Furthermore, in our recently completed phase I clinical trial we report that CYT-6091, when administered intravenously, is well tolerated, traffics to solid tumors, and increases overall exposure to TNF without inducing the dose-limiting toxicity of the cytokine, hypotension. With CYT-6091 we are generating clinical proof of concept for the use of colloidal gold nanoparticles for the development of systemically administrable Building on the early success of CYT-6091 our second-generation nanomedicine, CYT-20000, is engineered to deliver not only TNF but also chemotherapy to solid tumor. Our preclinical data support CYT-20000 may fully replicate the ILP paradigm as the TNF mediated targeting, afforded by the particle bound TNF, precedes the release of the of active chemotherapy from the particle
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version